Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Medtronic
AstraZeneca
Johnson and Johnson
Dow

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Cabotegravir

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Cabotegravir?

Cabotegravir is an investigational drug.

There have been 17 clinical trials for Cabotegravir. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2017.

The most common disease conditions in clinical trials are HIV Infections, Acquired Immunodeficiency Syndrome, and Immunologic Deficiency Syndromes. The leading clinical trial sponsors are ViiV Healthcare, National Institute of Allergy and Infectious Diseases (NIAID), and GlaxoSmithKline.

There are twenty-eight US patents protecting this investigational drug and two hundred and seventeen international patents.

Recent Clinical Trials for Cabotegravir
TitleSponsorPhase
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)ViiV HealthcarePhase 3
Long-Acting Cabotegravir Plus VRC01LS for Viral Suppression in HIV-1-Infected AdultsNational Institute of Allergy and Infectious Diseases (NIAID)Phase 2
More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsNational Institute of Allergy and Infectious Diseases (NIAID)Phase 1/Phase 2

See all Cabotegravir clinical trials

Clinical Trial Summary for Cabotegravir

Top disease conditions for Cabotegravir
Top clinical trial sponsors for Cabotegravir

See all Cabotegravir clinical trials

US Patents for Cabotegravir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cabotegravir   Start Trial Substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives ViiV Healthcare Company (Wilmington, DE)   Start Trial
Cabotegravir   Start Trial Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives ViiV Healthcare Company (Wilmington, DE)   Start Trial
Cabotegravir   Start Trial Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Shionogi & Co., Ltd. (Osaka, JP) GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
Cabotegravir   Start Trial (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent Shionogi & Co., Ltd. (Osaka, JP) VIIV Healthcare Company (Research Triangle Park, NC)   Start Trial
Cabotegravir   Start Trial Processes and intermediates for carbamoylpyridone HIV integrase inhibitors Shionogi & Co., Ltd. (Osaka, JP) VIIV Healthcare Company (Research Triangle Park, NC)   Start Trial
Cabotegravir   Start Trial Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-ca- rboxylate and processes for the preparation thereof Shionogi & Co., Ltd. (Osaka, JP) VIIV Healthcare Company (Research Triangle Park, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cabotegravir

Drugname Country Document Number Estimated Expiration Related US Patent
Cabotegravir China 102933080 2030-03-23   Start Trial
Cabotegravir Cyprus 1119143 2030-03-23   Start Trial
Cabotegravir Denmark 2549870 2030-03-23   Start Trial
Cabotegravir European Patent Office 2549870 2030-03-23   Start Trial
Cabotegravir European Patent Office 3260457 2030-03-23   Start Trial
Cabotegravir Spain 2632346 2030-03-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
AstraZeneca
Medtronic
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.